More relevant, the treatment with this agonist resulted in inhibition of lung metastasis in head and neck squamous cell carcinoma (HNSCC) mouse models, supporting the use of NR2F1 agonists to induce dormancy as a therapeutic strategy to prevent metastasis [213]. Here, NR2F1 is linked to head and neck squamous cell carcinoma.